Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) has announced significant progress in its pre-clinical program for developing therapeutics for trauma-related mental health disorders, particularly Post-Traumatic Stress Disorder (PTSD). The program, executed in collaboration with Graft Polymer, has identified two chemical series as co-leads for further development and established their synthesis pathways. Awakn has selected Charnwood Discovery as its synthesis partner and filed a provisional patent for a new class of aminoindane chemical entities and their derivatives. This progress aims to address the needs of approximately 13 million adults in the U.S. and 20 million collectively in key international markets affected by PTSD.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) ha annunciato significativi progressi nel suo programma preclinico per lo sviluppo di terapie per i disturbi mentali legati al trauma, in particolare Disturbo da Stress Post-Traumatico (PTSD). Il programma, eseguito in collaborazione con Graft Polymer, ha identificato due serie chimiche come co-lead per ulteriori sviluppi e ha stabilito i loro percorsi di sintesi. Awakn ha selezionato Charnwood Discovery come partner per la sintesi e ha depositato un brevetto provvisorio per una nuova classe di entità chimiche aminoindane e i loro derivati. Questo progresso mira a soddisfare le esigenze di circa 13 milioni di adulti negli Stati Uniti e 20 milioni complessivamente nei principali mercati internazionali colpiti da PTSD.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) ha anunciado avances significativos en su programa preclínico para desarrollar terapias para trastornos mentales relacionados con el trauma, especialmente Trastorno de Estrés Postraumático (PTSD). El programa, realizado en colaboración con Graft Polymer, ha identificado dos series químicas como co-líderes para un desarrollo posterior y ha establecido sus vías de síntesis. Awakn ha seleccionado Charnwood Discovery como socio de síntesis y ha presentado una patente provisional para una nueva clase de entidades químicas aminoindanas y sus derivados. Este progreso tiene como objetivo abordar las necesidades de aproximadamente 13 millones de adultos en EE. UU. y 20 millones en total en los principales mercados internacionales afectados por PTSD.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF)는 외상 후 스트레스 장애(PTSD)와 같은 외상 관련 정신 건강 장애에 대한 치료제를 개발하기 위한 사전 임상 프로그램에서 중요한 진전을 발표했습니다. Graft Polymer와의 협력으로 진행된 이 프로그램은 추가 개발을 위한 두 가지 화학 계열을 공동 주도로 확인하고 이들의 합성 경로를 설정했습니다. Awakn은 Charnwood Discovery를 합성 파트너로 선택하고 아미노인단 화학 물질 및 그 유도체의 새로운 클래스에 대해 잠정 특허를 출원했습니다. 이 진전은 PTSD로 영향을 받는 약 1,300만 명의 미국 성인과 주요 국제 시장에서 총 2,000만 명의 요구를 해결하는 것을 목표로 합니다.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) a annoncé des progrès significatifs dans son programme préclinique de développement de thérapies pour les troubles mentaux liés aux traumatismes, en particulier le trouble de stress post-traumatique (TSPT). Le programme, réalisé en collaboration avec Graft Polymer, a identifié deux séries chimiques comme co-leads pour un développement ultérieur et établi leurs voies de synthèse. Awakn a sélectionné Charnwood Discovery comme partenaire de synthèse et a déposé une demande de brevet provisoire pour une nouvelle classe d'entités chimiques aminoindanes et leurs dérivés. Ce progrès vise à répondre aux besoins d'environ 13 millions d'adultes aux États-Unis et 20 millions au total sur les principaux marchés internationaux touchés par le TSPT.
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) hat bedeutende Fortschritte in seinem präklinischen Programm zur Entwicklung von Therapeutika für traumaassoziierte psychische Erkrankungen, insbesondere Posttraumatische Belastungsstörung (PTBS), bekannt gegeben. Das Programm, das in Zusammenarbeit mit Graft Polymer durchgeführt wird, hat zwei chemische Serien als Co-Leads für die weitere Entwicklung identifiziert und deren Synthesewege festgelegt. Awakn hat Charnwood Discovery als Synthesepartner ausgewählt und ein vorläufiges Patent für eine neue Klasse von Aminoindanschwelldrogen und deren Derivaten angemeldet. Dieser Fortschritt soll die Bedürfnisse von etwa 13 Millionen Erwachsenen in den USA und 20 Millionen insgesamt auf den wichtigsten internationalen Märkten decken, die von PTBS betroffen sind.
- Identification of two chemical series as co-leads for further development
- Successful establishment of synthesis pathways for the compounds
- Selection of Charnwood Discovery as synthesis partner
- Filing of a provisional patent for a new class of aminoindane chemical entities
- None.
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to provide an update on the progress of its pre-clinical program being executed as part of a commercial collaboration with Graft Polymer (UK) Plc (LSE: GPL) ("Graft Polymer"), an innovative healthcare industry services company.
The collaboration focuses on developing a new class of therapeutics for the potential treatment of trauma-related mental health disorders, such as Post-Traumatic Stress Disorder ("PTSD"), which affects approximately 13 million adults in the U.S. and 20 million collectively in the US and other key international markets.
Recent progress includes:
- Lead chemical series identified: Two chemical series have been identified as co-leads for further development. These series represent a promising new class of compounds with the potential to improve treatment options for trauma-related mental health disorders such as PTSD. The selection of these co-lead candidates is a pivotal step in the drug development process.
- Synthesis pathways defined: The synthesis pathways for these compounds successfully established. This achievement is crucial, as it enables efficient and scalable production of the drug candidates, which will be essential as the collaboration moves towards more advanced pharmacological testing.
- Charnwood Discovery selected as synthesis partner: Awakn has selected Charnwood Discovery, a respected UK-based provider of drug discovery services, as its synthesis partner. The selection of Charnwood Discovery, known for its technical expertise, ensures that the synthesis process will be conducted to a high standard.
- New provisional patent filed: On 27 August 2024, Awakn filed a provisional patent application with the US Patent and Trademark Office, covering a new class of aminoindane chemical entities and their derivatives. This provisional patent has been incorporated into the scope of the commercial collaboration agreement between the Company and Awakn. This filing strengthens the intellectual property portfolio underpinning the Graft Polymer-Awakn collaboration, further reinforcing the Company's competitive edge in the biopharmaceutical market.
Anthony Tennyson, CEO of Awakn Life Sciences, commented: "We are making great strides in our collaboration with Graft Polymer as we move closer to developing a new class of therapeutics to tackle PTSD and other trauma-related conditions. These advancements represent a major step forward in our mission to deliver more effective solutions for those suffering from mental health disorders."
About Awakn Life Sciences Corp.
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing therapeutics targeting substance use and mental health disorders. Awakn has a near-term focus on AUD , a condition affecting approximately 29 million adults in the US and approximately 40 million in the US and key European markets for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
www.awaknlifesciences.com | LinkedIn | X (formerly Twitter)
About Graft Polymer (UK) Plc
Graft Polymer Plc is an innovative healthcare services company dedicated to helping biopharmaceutical companies specializing in central nervous system disorders enhance the effectiveness of their therapeutics.
www.graftpolymer.co.uk | LinkedIn | X (formerly Twitter)
Notice Regarding Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include, but are not limited to: fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Investor Enquiries:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony@awaknlifesciences.com
416-270-9566
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221298
FAQ
What progress has Awakn Life Sciences (AWKNF) made in its aminoindane pre-clinical program?
What is the target market size for Awakn's (AWKNF) PTSD treatment in development?
When did Awakn Life Sciences (AWKNF) file its provisional patent for aminoindane chemical entities?
Who is Awakn Life Sciences (AWKNF) collaborating with for its pre-clinical program?
